A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis After Hematopoietic Cell Transplantation
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-1443
Full Text
Open PDFAbstract
Available in full text
Date
September 16, 2015
Authors
Publisher
American Association for Cancer Research (AACR)